We are pleased to announce that on 08/11/2022 a Scientific Cooperation Agreement was signed between the M. Skłodowska-Curie National Research Institute of Oncology Gliwice Branch and the consortium: Acellmed Sp. z o.o. and Silesian Park of Medical Technology Kardio-Med Silesia. The scientific cooperation will consist in verifying the therapeutic activity and specificity of action of the anti-acute myeloid leukemia (AML) drug being developed by the Acellmed – ŚPTM Kardio-Med Silesia consortium on leukemic cells of AML patients being treated at the M. Skłodowska-Curie National Research Institute of Oncology Gliwice Branch.
The project to develop drug against AML: ” Personalized liposome-based small inhibitor RNA therapy for acute myeloid leukemia (OBS/AML)” is financial by the Office of the Marshal – Silesian Center for Entrepreneurship through of the competition of the RPO 1.2 WSL.